Ofichem 收购美国原料药 CDMO Kinentia Biosciences
Ofichem acquires US drug substance CDMO Kinentia
荷兰 Ofichem 已同意收购美国原料药 CDMO Kinentia Biosciences，交易尚待 CFIUS 批准及其他惯例交割条件。Kinentia 位于纽约州 Rensselaer，收购完成后其客户可使用 Ofichem 位于荷兰 Ter Apel 的设施进行工艺放大、法规支持和 GMP 生产。交易财务条款未披露。
pharmafile | October 14, 2026 | News story | | Biotechnology, CDMO, Pharmacy, acquisitions, drug substance development
Ofichem has agreed to acquire Kinentia Biosciences, a US drug substance contract development and manufacturing organisation (CDMO), in a deal that will give the Dutch company an operational presence in the US.
Kinentia, based in Rensselaer, New York, supports pharmaceutical and biotechnology companies with early-stage development, preclinical programmes and clinical development activities. The transaction remains subject to approval from the Committee on Foreign Investment in the United States (CFIUS) and other customary closing conditions.
The acquisition will complement Ofichem’s existing drug substance process development and GMP manufacturing capabilities in Europe. Following completion, Kinentia customers will be able to access Ofichem’s facilities in Ter Apel, the Netherlands, for process scale-up, regulatory support and GMP manufacturing.
Ofichem said the US presence would also allow it to work more closely with existing US customers and provide greater flexibility over where development and manufacturing activities take place. The company cited increasing interest in supply chain resilience and regional manufacturing as factors behind the expansion.
The deal will broaden Ofichem’s scientific capabilities to include polysaccharides, small peptides and complex new chemical entities, alongside its existing work in small molecules, highly potent compounds requiring OEB 3-5 controls, oligonucleotides and targeted protein degradation technologies including proteolysis-targeting chimeras (PROTACs).
Subject to the necessary licences and approvals, Ofichem also intends to explore establishing US capabilities for controlled substances.
Following completion, its drug substance business will operate from sites in New York, Ter Apel and Uppsala, Sweden, covering activities from early scientific and analytical development through process development, scale-up and GMP manufacturing.
Dr Weite Oldenziel, CEO of the Ofichem Group, said the acquisition would strengthen the company’s US presence while complementing its European development and manufacturing capabilities.
Financial terms of the transaction were not disclosed.
Pic: Andrew Patrick/Jan VanDerWolf
来源：Pharmafile · pharmafile.com